ARV-102 is a novel oral PROTAC protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2.
Arvinas has announced that the first subject was dosed in its Phase I clinical trial of ARV-102, according to a company press release.1 ARV-102 is the company’s first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases.
In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson’s disease and progressive supranuclear palsy.
According to the press release, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90% in non-human primates.
“Parkinson’s disease and progressive supranuclear palsy are devastating diseases and this important step of dosing the first healthy volunteer with ARV-102 marks a significant milestone in our commitment to develop transformative therapies for patients living with neurodegenerative diseases,” said Angela M. Cacace, PhD, senior vice president, neuroscience and platform biology, Arvinas in the press release. “There is a high unmet need in many neurologic diseases, and unlike other therapeutic modalities designed to inhibit LRRK2 activity, ARV-102 is an investigational oral PROTAC degrader uniquely designed to cross the blood-brain barrier and degrade the LRRK2 protein. As a pioneer in targeted protein degradation, we believe that PROTAC degraders have great potential to change the treatment paradigm for patients with neurodegenerative diseases.”
The Phase I trial of ARV-102 will evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics, including the evaluation of LRRK2 degradation and exploratory LRRK2 pathway biomarkers in healthy volunteers. The study is enrolling healthy volunteers at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.
Paxlovid Postexposure Prophylaxis Not Found to Significantly Lower Risk of Symptomatic SARS-CoV-2
July 19th 2024Paxlovid was the first oral drug approved by the FDA to treat Covid-19 in adults who do not require supplemental oxygen and who have an increased risk of progression to severe disease.
Altuviiio Shows Sustained Protection Against Bleeding Episodes in Children with Severe Hemophilia A
July 18th 2024Altuviiio is a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes in adults and children with hemophilia.